Replimune (REPL) Interest Coverage Ratio (2017 - 2026)
Replimune (REPL) reported Interest Coverage Ratio of 283.16 for Q1 2026, down 421.5% on a YoY basis from 88.07 in Q1 2025, and down 16295.43% sequentially from 1.73 in Q4 2025.
Replimune (REPL) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
Replimune (REPL) has 10 years of Interest Coverage Ratio data on file, last reported at 283.16 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio fell 421.5% year-over-year to 283.16; the trailing twelve-month figure through Mar 2026 stood at 118.36 (changed 0.39% YoY), and the FY2026 full-year result was 1.03, up 13.15% from the prior year.
- Interest Coverage Ratio fell to 283.16 in Q1 2026, from 1.73 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1506.56 in Q1 2024 to a low of 283.16 in Q1 2026.
- A 5-year average of 72.55 and a median of 1.31 in 2024 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio surged 3005.38% in 2024 and plunged 421.5% in 2026, its largest moves.
- Tracing REPL's Interest Coverage Ratio over 5 years: stood at 0.84 in 2022, then sank by 43.37% to 1.2 in 2023, then retreated by 23.86% to 1.49 in 2024, then declined by 16.13% to 1.73 in 2025, then slumped by 16295.43% to 283.16 in 2026.
- Business Quant data shows REPL's Interest Coverage Ratio at 283.16 in Q1 2026, 1.73 in Q4 2025, and 1.99 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | -283.16 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -283.16 |
| Dec 31, 2025 | -1.73 |
| Sep 30, 2025 | -1.99 |
| Jun 30, 2025 | -2.10 |
| Mar 31, 2025 | -54.30 |
| Dec 31, 2024 | -1.49 |
| Sep 30, 2024 | -1.31 |
| Jun 30, 2024 | -1.25 |
| Mar 31, 2024 | 1,506.56 |
| Dec 31, 2023 | -1.20 |
| Sep 30, 2023 | -1.34 |
| Jun 30, 2023 | -1.15 |
| Mar 31, 2023 | -51.85 |
| Dec 31, 2022 | -0.84 |
| Sep 30, 2022 | -0.83 |
| Jun 30, 2022 | -0.80 |
| Mar 31, 2022 | 132.18 |
| Dec 31, 2021 | -0.57 |
| Sep 30, 2021 | -0.55 |
| Jun 30, 2021 | -0.51 |